How Many Doses Per Vial: Wolverine Stack Explained

How Many Doses Per Vial: Wolverine Stack Explained

Without precise reconstitution calculations, 40% of researchers exhaust peptide vials weeks earlier than planned. Not through wastage, but through dose miscalculation that turns what should be a controlled protocol into an inconsistent experiment. The Wolverine Peptide Stack combines BPC-157 and TB-500 (Thymosin Beta-4) at specific concentrations, and understanding exactly how many doses each vial yields determines whether your research maintains consistency or collapses mid-cycle.

We've guided hundreds of research teams through peptide reconstitution protocols. The gap between doing it right and doing it wrong comes down to three variables most product descriptions never clarify upfront.

How many doses are in a Wolverine Stack vial?

A standard Wolverine Stack vial from Real Peptides contains 5mg BPC-157 and 5mg TB-500. When reconstituted with 2mL bacteriostatic water, each vial yields 10–20 doses depending on your target dose per administration. 500mcg combined peptides per dose produces 10 administrations, while 250mcg produces 20. Reconstitution volume and target dose per injection are the only variables that determine total dose count.

Understanding Wolverine Stack Vial Composition

The Wolverine Stack isn't a single peptide. It's a synergistic combination designed to support tissue repair, recovery, and regeneration research. Each vial contains two distinct lyophilised peptides: BPC-157 (Body Protection Compound-157), a synthetic pentadecapeptide derived from gastric protective protein, and TB-500, the synthetic form of Thymosin Beta-4, a naturally occurring peptide present in nearly all mammalian cells. BPC-157 demonstrates mechanism of action through angiogenesis promotion and modulation of growth factor expression, particularly VEGF (vascular endothelial growth factor). TB-500 operates via actin-binding properties that facilitate cell migration, tissue remodelling, and extracellular matrix formation.

Real Peptides manufactures the Wolverine Stack with exact amino-acid sequencing through small-batch synthesis. Each 5mg portion represents pharmaceutical-grade purity verified through HPLC (high-performance liquid chromatography) testing. The lyophilised powder format maximises stability during storage and transport, with an average shelf life of 24–36 months when stored at −20°C before reconstitution. Once you add bacteriostatic water, that timeline compresses dramatically: refrigerated reconstituted peptides maintain potency for 28–30 days at 2–8°C, after which protein degradation accelerates regardless of visual appearance.

The 5mg + 5mg concentration isn't arbitrary. Research protocols commonly employ BPC-157 at 250–500mcg per administration and TB-500 at matching or slightly higher concentrations. Combining them at equal milligram quantities in a single vial allows straightforward dosing arithmetic without requiring separate reconstitution calculations for each peptide. This is the format we've seen deliver the most consistent results across diverse research applications, from soft tissue injury models to gastrointestinal barrier integrity studies.

Reconstitution Math: How Volume Determines Dose Count

Reconstitution volume is the single variable that determines how many doses vial Wolverine Stack produces. The peptide content is fixed at 5mg + 5mg (total 10mg combined peptides). The volume of bacteriostatic water you inject into that vial creates the concentration. And concentration dictates how much liquid you must draw to achieve your target dose.

Standard reconstitution uses 2mL bacteriostatic water, producing a concentration of 5mg/mL total peptides (2.5mg/mL BPC-157 + 2.5mg/mL TB-500). If your research protocol requires 500mcg (0.5mg) combined peptides per dose, you draw 0.1mL (10 units on a U-100 insulin syringe). That 2mL vial yields exactly 20 draws at 0.1mL each. But only 10 doses if you're administering 1mg combined peptides per injection (0.2mL per dose).

Reconstituting with 1mL bacteriostatic water instead doubles the concentration to 10mg/mL. Now a 500mcg dose requires only 0.05mL (5 units), and the vial yields 20 administrations at that dose. The trade-off: higher concentrations mean smaller draw volumes, which increases measurement precision requirements and raises the likelihood of dosing error if your syringe increments aren't sufficiently granular. Most insulin syringes mark 1-unit increments (0.01mL), making 0.05mL draws manageable. But anything below that approaches the margin of error for manual measurement.

Here's the calculation framework: Total peptide mass (mg) ÷ Reconstitution volume (mL) = Concentration (mg/mL). Then: Target dose per administration (mg) ÷ Concentration (mg/mL) = Volume to draw per dose (mL). Finally: Total reconstitution volume (mL) ÷ Volume per dose (mL) = Total number of doses. For the Wolverine Stack reconstituted with 2mL at a 500mcg target dose: 10mg ÷ 2mL = 5mg/mL. 0.5mg ÷ 5mg/mL = 0.1mL per dose. 2mL ÷ 0.1mL = 20 doses.

One critical detail most reconstitution guides omit: dead space. Every vial retains approximately 0.05–0.1mL of liquid that cannot be drawn even when inverted. Trapped by surface tension and vial geometry. That represents 1–2 doses lost to dead space in a 2mL reconstitution, reducing the practical yield from 20 theoretical doses to 18–19 actual doses. Low dead space syringes and drawing technique (inserting the needle at a 45-degree angle during the final draw) recover some of this loss, but never all of it.

Dosing Protocols: Frequency and Duration

How many doses vial Wolverine Stack provides depends not just on reconstitution math but on administration frequency. Research protocols vary widely. Some employ daily dosing during acute injury phases, others use every-other-day administration for maintenance or longer-duration studies.

Daily dosing at 500mcg combined peptides (250mcg BPC-157 + 250mcg TB-500) exhausts a single 2mL-reconstituted vial in 18–20 days accounting for dead space loss. If your research timeline extends beyond three weeks, you'll need at minimum two vials. Every-other-day dosing at the same 500mcg dose stretches one vial across 36–40 days. Sufficient for a standard 4–6 week pilot study without requiring mid-protocol vial replacement.

Higher-dose protocols. Particularly those targeting 1mg combined peptides per administration. Halve these timelines. A 2mL vial yields only 9–10 usable doses at 1mg per injection, covering 9–10 days of daily dosing or 18–20 days of every-other-day administration. We've observed research teams miscalculate supply requirements at this dose tier more than any other, often ordering insufficient vials and introducing 3–5 day gaps while awaiting restocking. Gaps that disrupt steady-state tissue concentration and compromise protocol continuity.

Weekly dosing, sometimes employed in longitudinal regenerative studies, extends one vial across 18–20 weeks at 500mcg per dose. But introduces a separate challenge. Reconstituted peptides stored at 2–8°C maintain potency for approximately 28–30 days, meaning weekly protocols require either accepting potency degradation after week 4 or reconstituting smaller batches in sequence. Lyophilised peptides are stable for years; reconstituted peptides are perishable. The mathematics of dose count must account for both.

Dose stacking. Administering BPC-157 and TB-500 as separate injections rather than combined. Doesn't change total dose count but does alter administration logistics. If you reconstitute each peptide in its own vial rather than using the pre-combined Wolverine Stack, you'll draw from two vials per administration session instead of one. This doubles syringe usage and injection site rotations but allows independent dose titration if your research question requires asymmetric peptide ratios.

Wolverine Stack Dosing: Protocol Comparison

Understanding how reconstitution choices interact with dosing frequency clarifies exactly how long one vial supports your research timeline. Below is a practical comparison of common protocol configurations.

The 'Practical Doses' column reflects real-world vial yield after accounting for dead space retention. The residual 0.05–0.1mL that remains in the vial even with optimal drawing technique. Notice that higher reconstitution volumes don't increase total doses at a given target dose; they only alter the draw volume per administration. A 500mcg dose from a 2mL reconstitution requires 0.1mL per draw, while the same 500mcg dose from a 1mL reconstitution requires only 0.05mL. But both configurations yield approximately 18–19 usable doses because the peptide mass and target dose are identical.

Key Takeaways

• A single Wolverine Stack vial contains 5mg BPC-157 and 5mg TB-500, totaling 10mg combined lyophilised peptides before reconstitution.
• Reconstituting with 2mL bacteriostatic water produces a 5mg/mL concentration; 500mcg target dose requires 0.1mL per administration, yielding 18–19 practical doses per vial.
• Dead space retention in every vial traps 0.05–0.1mL of reconstituted solution, reducing theoretical dose count by 1–2 administrations regardless of reconstitution volume.
• Daily dosing at 500mcg combined peptides exhausts one 2mL-reconstituted vial in 18–19 days; every-other-day dosing extends the same vial to 36–38 days.
• Reconstituted peptides maintain potency for 28–30 days when refrigerated at 2–8°C. Protocols extending beyond one month require sequential vial reconstitution even if dose count mathematically supports longer duration.
• Higher-dose protocols (1mg per administration) halve vial longevity: one 2mL vial yields only 9–10 usable doses, covering 9–10 days of daily administration.

What If: Wolverine Stack Dosing Scenarios

What If I Accidentally Reconstitute with 3mL Instead of 2mL?

Draw 0.15mL per dose instead of 0.1mL to maintain the same 500mcg target. The concentration drops to 3.33mg/mL (10mg ÷ 3mL), so compensating requires proportionally larger draw volumes. Your dose count remains the same. Still approximately 18–20 usable doses. But each administration uses 50% more liquid volume. The primary risk isn't underdosing if you adjust draw volume correctly; it's injecting larger subcutaneous volumes that may increase injection site discomfort or slower absorption kinetics in some tissue models.

What If I Need to Extend One Vial Across 60 Days?

Switch to every-third-day dosing at 500mcg, which stretches 18–19 doses across 54–57 days. Close to your target. Alternatively, reduce dose to 250mcg and administer every other day: one vial yields 38–39 doses, covering 76–78 days. The trade-off is lower per-administration peptide concentration, which may alter tissue-level pharmacokinetics depending on your research model. Weekly dosing would extend one vial past 60 days mathematically, but reconstituted peptides degrade significantly after 28–30 days refrigerated. You'd be administering degraded peptides for half the protocol duration.

What If My Research Requires Separate BPC-157 and TB-500 Dosing Ratios?

Purchase BPC-157 and TB-500 as individual peptides rather than the pre-combined Wolverine Stack. This allows independent reconstitution and dose titration. For example, 500mcg BPC-157 daily but only 250mcg TB-500 twice weekly. The combined stack is cost-effective and logistically simpler for symmetrical dosing, but asymmetric protocols demand separate vials. Reconstitute each peptide in its own vial, calculate doses independently, and track expiration dates for both. One peptide vial may exhaust weeks before the other depending on your administration frequency.

What If I Draw 0.12mL by Mistake Instead of 0.1mL?

You've administered 600mcg instead of 500mcg. A 20% overdose. For a single occurrence, this rarely disrupts research outcomes in regenerative tissue models, but repeated measurement errors compound quickly. If this happens on 5 of 20 planned doses, you'll exhaust the vial at dose 17 instead of dose 20, forcing either a 3-day protocol gap or emergency reordering. The fix: verify syringe calibration before every draw, and consider switching to 1mL tuberculin syringes with finer graduation marks (0.01mL increments clearly visible) if insulin syringe markings are difficult to read under your lab lighting conditions.

The Practical Truth About Wolverine Stack Dosing

Here's the honest answer: most researchers overestimate how many doses they'll extract from a vial and underestimate how quickly daily protocols exhaust supply. The math says 20 doses; the reality is 18–19 after dead space loss. The product label says 28–30 day refrigerated stability; the reality is that potency begins measurable decline after day 21 even when stored correctly. If you're planning a 30-day daily protocol at 500mcg per dose, order two vials. Not one. Because the second vial starts fresh at full potency when the first vial enters its degradation window.

Reconstitution isn't the hard part. Matching your vial inventory to your actual protocol timeline without introducing gaps or using degraded peptides. That's where most studies stumble. A consistent 28-day cycle with fresh peptides throughout outperforms a 35-day cycle where the final week uses peptides stored past their stability threshold. The Wolverine Stack's dual-peptide format simplifies administration logistics, but it doesn't eliminate the need for precise supply planning. Calculate backward from your protocol endpoint: how many total administrations, at what dose, over how many days. Then round up, not down, when ordering vials.

Bacteriostatic water volume matters less than most researchers assume. Whether you use 1mL or 2mL, the total doses per vial remain nearly identical at any given target dose. Only the draw volume per administration changes. What actually determines how many doses vial Wolverine Stack delivers is the target dose itself and how much peptide you lose to dead space and measurement variance. A 250mcg protocol yields twice the administrations of a 500mcg protocol from the same vial. A 1mg protocol halves it again. The peptide quantity is fixed; your dosing decisions control everything else.

If you're weighing whether the Wolverine Peptide Stack fits your research model, compare it against standalone BPC-157 or TB-500 based on whether your protocol demands symmetrical or asymmetrical peptide ratios. For recovery and regenerative tissue studies where both peptides target the same physiological endpoints at comparable doses, the combined stack eliminates redundant reconstitution steps and halves injection frequency. For research questions requiring independent peptide titration or staggered administration schedules, individual vials provide the control the stack format cannot.

The broader lesson: peptide research fails less often from poor science than from poor logistics. Running out of supply mid-protocol, using peptides stored past stability windows, or miscalculating doses due to unclear reconstitution arithmetic. These aren't minor inconveniences. They're confounding variables that corrupt data integrity as thoroughly as contamination or temperature excursions. Real Peptides provides the tools and compounds necessary for rigorous biological research, but precise execution still depends on matching vial inventory and reconstitution strategy to your specific timeline and dose requirements. Calculate once, order correctly, and administer consistently. That's the protocol that separates publishable findings from wasted bench time.